Patent intelligence · US
US 11697667
Salts and polymorphs of cethromycin for the treatment of disease
Salts and polymorphs of cethromycin for the treatment of disease
Patent details — US 11697667
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 11, 2023
- Expiration
- Jul 6, 2043
- Applicant
- AliquantumRx, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/7048, A61K31/706, A61P
Quick answer
US 11697667 (Salts and polymorphs of cethromycin for the treatment of disease) is held by AliquantumRx, Inc.. Status: granted. Granted Jul 11, 2023. Expires Jul 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AliquantumRx, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/7048, A61K31/706, A61P, A61P31/04, A61P33/06
More from AliquantumRx, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12391720
Salts and polymorphs of cethromycin for the treatment of disease
granted -
US 12377151
Immobilized endoglycosidase fusion protein and use thereof
granted -
US 12370266
Polymer composite nanomaterial encapsulation system
granted -
US 12318457
Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof
granted -
US 12312377
Biconjugatable labels and methods of use
granted -
US 12195454
Compounds for imaging tau proteins that accumulate in the brain
granted -
US 12102694
Radiolabeled compound producing method and producing apparatus, radiolabeled compound and radioisotope producing apparatus
granted -
US 11999748
Exatecan derivatives, linker-payloads, and conjugates and thereof
granted
Frequently asked questions
What is US patent 11697667?
US 11697667 (Salts and polymorphs of cethromycin for the treatment of disease) is held by AliquantumRx, Inc.. Status: granted. Granted Jul 11, 2023. Expires Jul 6, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11697667?
AliquantumRx, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 11697667 expire?
Our index shows an expiration date of Jul 6, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.